Evidence map›Paper›PMID 38427251›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2024

Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis: Clinical Protocol and Evaluation of Microbiota Immunity Axis.

Elena Niccolai, Ilaria Martinelli, Gianluca Quaranta, Giulia Nannini, Elisabetta Zucchi, Flavio De Maio, Giulia Gianferrari, Stefano Bibbò, Giovanni Cammarota, Jessica Mandrioli and 2 more

Open access · greenAbstract readClinical Trial Protocol
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
23.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Elena NiccolaiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Ilaria MartinelliNeurology Unit, Department of Neuroscience, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
Gianluca QuarantaDepartment of Laboratory and Infectious Sciences, A. Gemelli University Hospital IRCCS, Rome, Italy.
Giulia NanniniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Elisabetta ZucchiDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Flavio De MaioDepartment of Laboratory and Infectious Sciences, A. Gemelli University Hospital IRCCS, Rome, Italy.
Giulia GianferrariDepartment of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Stefano BibbòDigestive Disease Center, A. Gemelli University Hospital IRCCS, Catholic University of Sacred Heart, Rome, Italy.
Giovanni CammarotaDigestive Disease Center, A. Gemelli University Hospital IRCCS, Catholic University of Sacred Heart, Rome, Italy.
Jessica MandrioliNeurology Unit, Department of Neuroscience, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
Luca MasucciDepartment of Laboratory and Infectious Sciences, A. Gemelli University Hospital IRCCS, Rome, Italy. luca.masucci@policlinicogemelli.it.
Amedeo AmedeiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy. amedeo.amedei@unifi.it.
Università Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · ITAzienda Ospedaliero-Universitaria di Modena · ITUniversity of Florence · ITUniversity of Modena and Reggio Emilia · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fecal microbial transplantation (FMT) is a therapeutic transplant of fecal microbiota from healthy donors to patients. This practice is aimed at restoring eubiosis and rebalancing the enteric and systemic immune responses, and then eliminating pathogenic triggers of multiple disease, including neurodegenerative diseases. Alterations of gut microbiota (GM) affect the central nervous system (CNS) health, impacting neuro-immune interactions, synaptic plasticity, myelination, and skeletal muscle function. T-regulatory lymphocytes (Treg) are among the most important players in the pathogenesis of amyotrophic lateral sclerosis (ALS), altering the disease course. Along with circulating neuropeptides, other immune cells, and the gut-brain axis, the GM influences immunological tolerance and controls Treg's number and suppressive functions. A double-blind, controlled, multicenter study on FMT in ALS patients has been designed to evaluate if FMT can modulate neuroinflammation, by restoring Treg number, thus modifying disease activity and progression.

Indexed as

Amyotrophic Lateral SclerosisGastrointestinal MicrobiomeMicrobiotaFecal Microbiota TransplantationHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicAmyotrophic lateral sclerosisClinical trialCulturomicsFlow cytometryInflammationMicrobiotaT-regulatory

Identifiers

PMID38427251
OpenAlexW4392398031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.